The cardiovascular system medicine sales in Canada are projected to decrease steadily from 2024 to 2028. The forecasted value for 2024 is 2.41 billion USD PPP and is expected to decline annually, reaching 2.05 billion USD PPP by 2028. This shows a year-on-year decrease in sales value: 3.73% in 2025, 3.88% in 2026, 4.04% in 2027, and 4.21% in 2028. The compound annual growth rate (CAGR) from 2023 to 2028 indicates an average annual decrease of approximately 3.96%.
In 2023, the sales of cardiovascular system medicines stood at 2.50 billion USD PPP. The notable downward trend over these years may be influenced by several factors, including market saturation, enhanced preventive healthcare, improvements in lifestyle reducing cardiovascular disease incidence, or increased competition from generic medicine offerings.
Future trends to watch include advancements in personalized medicine, the impact of new healthcare policies, shifts towards preventive cardiology, and technological innovations in cardiovascular treatments. Monitoring these aspects can provide further insights into the evolving market dynamics.